LINEAGE CELL THERAPEUTICS IN
LCTXNYSE AMERICAN🏆 #2833 by market capUS Equity
$902.82▲ $30.33 (+3.36%)
Simulated price1h—
24h▲ 3.4%
7d—
14d—
30d—
1y—
🏦Market Cap
$286M
Small Cap
📈Revenue Growth (YoY)
-37.1%
Declining
📊Gross Margin
94.1%
High
💵FCF Margin
—
⚖️P/S Ratio
19.5x
Expensive
Otter Score
58
Weak
No chart data available for LCTX.
Trading Snapshot
- Day Range
- $899.08 – $916.80
- 52-Week Range
- $0.95 – $2.09
- Volume
- $2.32B
- Avg Volume
- $1.63B
- Shares Outstanding
- 249.3M
- Next Earnings
- Oct 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $15M
- Last Q Revenue
- $4M
- P/E Ratio
- —
- P/S Ratio
- 19.5x
- EPS (TTM)
- $-0.28
- Dividend Yield
- —
Why Investors Own LCTX
- ✓High-growth profile — revenue up +24.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 36% gross margin and 23% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$15M▲ +28.5% YoY
Gross Margin (TTM)
35.9%▲ +0.3% YoY
Operating Income (TTM)
$2M▲ +28.5% YoY
Free Cash Flow (TTM)
$3M▲ +28.5% YoY
About LINEAGE CELL THERAPEUTICS IN
A company profile for LINEAGE CELL THERAPEUTICS IN isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
58/100
Analyst Price Target
ⓘAverage Target
$1,124.24
▲ +24.5% Upside
High Target$1,308.38
Low Target$953.61
Based on 36 analysts
Latest News & Updates
🚀
Reuters·2h ago
LINEAGE CELL THERAPEUTICS IN tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift LCTX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
LINEAGE CELL THERAPEUTICS IN announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.